[{"id":"7fc864bc-2037-4926-9819-2552b751ef5d","acronym":"ATTAC-MCC","url":"https://clinicaltrials.gov/study/NCT03747484","created_at":"2021-06-30T14:53:31.876Z","updated_at":"2024-07-02T16:35:12.716Z","phase":"Phase 1/2","brief_title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","source_id_and_acronym":"NCT03747484 - ATTAC-MCC","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2025","study_completion_date":" 01/10/2025","last_update_posted":"2024-03-26"}]